Simlosin Special Precautions

As with other α-adrenoreceptor antagonists, a decrease in blood pressure may occur in certain individuals during therapy with tamsulosin hydrochloride, and may cause syncope (rare). When the initial symptoms of orthostatic hypotension (dizziness, weakness) occur, the patient should be seated or laid down until the complaints disappear. Before starting tamsulosin hydrochloride therapy, the patient needs to undergo examination to ensure that there are no certain conditions that can cause symptoms similar to benign prostatic hyperplasia (BPH). Rectal examination and if necessary prostate specific antigen (PSA) examination can be done before starting therapy or periodically during therapy. Treatment for patients with severely impaired renal function (creatinine clearance <10 mL/min) should be done with caution as there have been no studies in this group. Ophthalmologists should be aware of the occurrence of Intraoperative Floppy Iris Syndrome (IFIS) that occurs during cataract or glaucoma surgery in patients currently or recently taking tamsulosin hydrochloride. IFIS may increase the risk of eye complications during or after surgery. Tamsulosin hydrochloride should be temporarily discontinued for 1-2 weeks prior to cataract or glaucoma surgery, although the extent of benefit is unknown. IFIS has occurred in patients who have discontinued tamsulosin hydrochloride for a longer period before undergoing surgery. Patients who have been planned to undergo cataract or glaucoma surgery is not recommended to start therapy with tamsulosin hydrochloride. During the pre-operative assessment, the physician should ascertain whether the patient who is planning to undergo cataract or glaucoma surgery has received tamsulosin hydrochloride, to anticipate any possibility associated with the occurrence of IFIS during surgery. Tamsulosin hydrochloride should not be combined with strong CYP3A4 antagonists in patients with CYP2D6 metabolic deficiency - tamsulosin hydrochloride should be administered with caution when combined with strong and moderate strength CYP3A4 antagonists. There have been cases of allergic reactions to tamsulosin hydrochloride in patients with a history of allergy to sulfonamides. If the patient reports a previous history of sulfa allergy, Tamsulosin hydrochloride should be administered with caution. There is a possibility of metabolic waste of tamsulosin hydrochloride being found in the feces.